Product
TY-9591
Aliases
placebo TY-9591, placebo TY-9591 Tablets, TY-9591(10mg,40mg) qd. po, TY-9591 Tablets
6 clinical trials
5 indications
Indication
NSCLCIndication
Brain MetastasesIndication
Leptomeningeal MetastasisIndication
Healthy Control ParticipantsClinical trial
A Phase II, Open-label, Multi-center Study to Evaluate the Efficacy and Safety of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain or Leptomeningeal MetastasesStatus: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase III, Randomised, Double-blind, Multi-center Study to Assess the Efficacy and Safety of TY-9591 Tablets Versus Osimertinib as First Line Treatment in Patients With EGFR-sensitive Mutation, Locally Advanced or Metastatic Non Small Cell Lung Cancer.Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
Studies to Compare the Pharmacokinetics of TY-9591 Tablets and Osimertinib Mesylate Tablets After a Single Fasting Administration and Determine the Effect of Food on the Pharmacokinetics of TY-9591 Tablets in Healthy VolunteersStatus: Completed, Estimated PCD: 2021-09-09
Clinical trial
Phase I, Open-label, Single-arm Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Preliminary Efficacy of TY-9591 Tablets in Advanced NSCLC Patients With Epidermal Growth Factor Receptor( EGFR) Positive MutationStatus: Completed, Estimated PCD: 2023-03-03
Clinical trial
[14 C] Study on Mass Balance of TY-9591 in Healthy Chinese Adult Male SubjectsStatus: Recruiting, Estimated PCD: 2024-03-15
Clinical trial
A Phase II Study of TY-9591 Tablets in Patients With EGFR-Mutated Non-small Cell Lung Cancer With Brain MetastasesStatus: Recruiting, Estimated PCD: 2025-06-30